European Journal of Cancer
Volume 38 , Pages 3-9 , February 2002

Rational development of capecitabine

  • M Venturini

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39-010-5600-666; fax: +39-010-5600-850

Received 25 June 2001 ,Revised 26 November 2001 ,Accepted 30 November 2001.

References 

  1. Diasio R. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacol. 1989;16:215–237
  2. Schalhorn A, Kuhl M. Clinical pharmacokinetics of fluorouracil and folinic acid. Semin. Oncol. 1992;19(Suppl. 3):82–92
  3. Allegra CJ, Grem JL. Antimetabolites. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer, Principles and Practice of Oncology. 5th edn.. Philadelphia: Lippincott-Raven; 1997;p. 432–452
  4. Cameron DA, Gabra H, Leonard RC. Continuous 5-fluorouracil in the treatment of breast cancer. Br. J. Cancer. 1994;70:120–124
  5. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann. Oncol. 1996;7:807–813
  6. Smith IE. Continuous infusional chemotherapy for early breast cancer (the Royal Marsden Hospital experience). Recent Results Cancer Res. 1998;152:323–327
  7. Caudry M, Bonnel C, Floquet A, et al.  A randomised study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am. J. Clin. Oncol. 1995;18:118–125
  8. Leichman CG, Fleming TR, Muggia FM, et al.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer (a Southwest Oncology Group Study). J. Clin. Oncol. 1995;13:1303–1311
  9. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma (a Mid-Atlantic Oncology Program study). J. Clin. Oncol. 1989;7:425–432
  10. Rougier P, Paillot B, LaPlanche A, et al.  5-fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur. J. Cancer. 1997;33:1789–1793
  11. Meta-analysis Group in Cancer . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998;16:301–308
  12. Meta-analysis Group in Cancer . Toxicity of fluorouracil in patients with advanced colorectal cancer (effect of administration schedule and prognostic factors). J. Clin. Oncol. 1998;16:3537–3541
  13. Adjei AA. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br. J. Clin. Pharmacol. 1999;48:265–277
  14. Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology. 1998;10(Suppl. 7):39–43
  15. Diasio R. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs. 1999;58(Suppl. 3):119–126
  16. Hoff M, Royce M, Medgyesy D, Brito R, Pazdur R. Oral fluoropyrimidines. Semin. Oncol. 1999;26:640–646
  17. MacDonald JS. Oral fluoropyrimidines. A closer look at their toxicities. Am. J. Clin. Oncol. 1999;22:475–480
  18. Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur. J. Cancer. 1998;34:1509–1513
  19. Rustum YM, Cao S. New drugs in therapy of colorectal cancer (preclinical studies). Semin. Oncol. 1999;26:612–620
  20. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med. 1992;35:1505–1509
  21. Liu G, Franssen E, Fitch MI, Warner E. Patient preference for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997;15:110–115
  22. Borner M, Schöffski P, de Wit R, et al. A randomised crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 2000, 19, 191a (abstr 741).
  23. Judson IR, Beale PJ, Trigo JM, et al.  A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest. New Drugs. 1999;17:49–56
  24. Folkman J. What is the role of thymidine phosphorylase in tumour angiogenesis?. J. Natl. Cancer Inst. 1996;88:1091–1092
  25. Ishikawa F, Miyazono K, Hellman U, et al.  Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989;338:557–562
  26. Sumizawa T, Furukawa T, Haraguchi M, et al.  Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem. (Tokyo). 1993;114:9–14
  27. Moghaddam A, Zhang HT, Fan TPD, et al.  Thymidine phosphorylase is angiogenic and promotes tumour growth. Proc. Natl. Acad. Sci. USA. 1995;92:998–1002
  28. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int. J. Cancer. 1995;64:79–82
  29. Kitazono M, Takebayashi Y, Ishitsuka K, et al.  Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem. Biophys. Res. Commun. 1998;253:797–803
  30. Miwa M, Ura M, Nishida M, et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 1998;34:1274–1281
  31. Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F, Ishisuka H. Antitumour activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine). Biol. Pharm. Bull. 1998;21:713–717
  32. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumours in human cancer xenografts. Cancer Res. 1998;58:685–690
  33. Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and-resistant tumours. Proc Am Soc Clin Oncol 1997, 16, 226a (abstr 795).
  34. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin. Cancer Res. 1998;4:1013–1019
  35. Endo M, Shinbori N, Fukase Y, et al.  Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumour models. Int. J. Cancer. 1999;83:127–134
  36. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res. 1999;5:2948–2953
  37. Wilke H. Future treatment options with capecitabine in solid tumours. Eur J Cancer 2002, 38, 21–25 (suppl).
  38. Schüller J, Cassidy J, Dumont E, et al.  Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 2000;45:291–297
  39. Cassidy J, Twelves C, Cameron D, et al.  Bioequivalance of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother. Pharmacol. 1999;44:453–460
  40. Reigner B, Verweij J, Dirix L, et al.  Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin. Cancer Res. 1998;4:918–941
  41. Twelves C, Glynne-Jones R, Cassidy J, et al.  Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. 1999;5:1696–1702
  42. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 2001;40:85–104
  43. Budman DR, Meropol NJ, Reigner B, et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate (capecitabine). J. Clin. Oncol. 1998;16:1795–1802
  44. Frings S. Capecitabine — a novel oral tumour-activated fluoropyrimidine. Onkologie. 1998;21:451–458
  45. Reigner B, Clive S, Cassidy J, et al.  Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother. Pharmacol. 1999;43:309–315
  46. Cassidy J, Dirix L, Bisset D, et al.  A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin. Cancer Res. 1998;4:2755–2761
  47. Mackean M, Planting A, Twelves C, et al.  Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 1998;16:2977–2985
  48. Van Cutsem E, Findlay M, Osterwalder B, et al.  Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer (results of a randomized phase II study). J. Clin. Oncol. 2000;18:1337–1345
  49. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two randomised, phase III trials. Eur J Cancer 2002, 38, 15–20 (suppl.).
  50. Begg C, Cho M, Eastwood S, et al.  Improving the quality of reporting of randomised controlled trials: the CONSORT statement. JAMA. 1996;276:637–639

PII: S0959-8049(01)00414-2

European Journal of Cancer
Volume 38 , Pages 3-9 , February 2002

Article Tools

* Image Usage & Resolution